阿帕替尼联合替吉奥诱导治疗局部晚期舌鳞癌的近期疗效

Short-term efficacy of apatinib combined with gimeracil and oteracil porassium capsules in induction therapy for locally advanced squamous cell carcinoma of the tongue

目的评价阿帕替尼联合替吉奥胶囊对局部晚期舌鳞癌患者术前诱导治疗的有效性和安全性。方法回顾性分析2017年3月至2018年12月于我院口腔颌面头颈肿瘤科就诊、口服阿帕替尼联合替吉奥胶囊治疗的9例局部晚期、初治舌鳞癌患者,评价其接受诱导治疗的局部疗效。患者接受诱导治疗后再行手术治疗,术后病理表现有高危因素者行术后放疗、定期随访,计算随访时间段内总生存率。结果9例患者接受诱导治疗局部疗效为:3例患者完全缓解,4例患者部分缓解,2例患者疾病稳定,诱导用药不良反应可控。诱导治疗后所有患者均行手术治疗,其中3例患者接受术后放疗。经7.9~26.1个月随访(中位随访16.1个月),2例复发,6例病情稳定,1例死亡。结论阿帕替尼联合替吉奥作为局部晚期舌鳞癌的诱导治疗选择,近期疗效满意,不良反应尚可接受。

Objective To evaluate the efficacy and safety of apatinib combined with gimeracil and oteracil porassium capsules in preoperative induction therapy for locally advanced tongue squamous cell carcinoma.Methods A retrospective analysis was made on 9 cases of locally advanced squamous cell carcinoma of the tongue treated by oral administration of apatinib combined with gimeracil and oteracil porassium capsules in the department of oral and maxillofacial-head and neck oncology,which in our hospital from March 2017 to December 2018.The local efficacy of induction therapy was evaluated and the patients were treated by surgery after induction therapy.Postoperative radiotherapy was performed for patients with high-risk factors of pathology after the operation.After treatment,follow-up was conducted regularly to evaluate the overall survival.Results The local efficacy of induction therapy in 9 patients was 3 cases of complete remission,4 cases of partial remission and 2 cases of stable disease.The adverse reaction of induction therapy were controllable.Surgery was performed after induction therapy,and postoperative radiotherapy was performed in 3 patients.After 7.9~26.1 months of follow-up(median follow-up of 16.1 months),2 cases recurred,6 cases were stable,and 1 case died.Conclusion Apatinib combined with gimeracil and oteracil porassium capsules as induction therapy for locally advanced squamous cell carcinoma of the tongue has satisfactory short-term efficacy and acceptable adverse reactions.